These limitations have recently been overcome with development of novel AD-specific blood biomarkers, where plasma levels of tau phosphorylated at various residues have been demonstrated to be specific and sensitive biomarkers of AD in CU individuals and individuals with mild cognitive impairment and AD dementia [5–14]. Here, MAPT is linked to Alzheimer disease.